Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Prognostic value of circulating nucleosomes during treatment with or without immunotherapy in Non-Small Cell Lung Cancer: results from Nucleo-Lung study

Saturday, September 14, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Nucleo-Lung study, presented at ESMO 2024, highlights the prognostic value of circulating nucleosomes in patients with Non-Small Cell Lung Cancer. The research suggests that these biomarkers could be beneficial in assessing treatment responses, particularly in the context of immunotherapy. The findings contribute valuable insights into cancer treatment monitoring.
Price reaction · baseline $13.592 (2024-09-13 close) · 1 other VNRX headline(s) in the window, move may be shared
day 0 close
+1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study presents promising prognostic data for Non-Small Cell Lung Cancer.
  • Circulating nucleosomes may enhance treatment monitoring and patient outcomes.
  • Findings were presented at a reputable conference, ESMO 2024.

Full Press Release Details

Poster titled: Prognostic value of circulating nucleosomes during treatment with or withoutimmunotherapy in Non-Small Cell Lung Cancer: results from Nucleo-Lung study
Presented at: ESMO 2024
Payen et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the Nucleo-Lung study about?

The Nucleo-Lung study investigates the prognostic value of circulating nucleosomes in Non-Small Cell Lung Cancer.

Where was the Nucleo-Lung study presented?

The study was presented at the ESMO 2024 conference.

What are circulating nucleosomes?

Circulating nucleosomes are fragments of DNA that can indicate cancer progression and treatment response.

How might nucleosomes help in cancer treatment?

They may enhance monitoring of treatment responses, especially in immunotherapy.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Non-Small Cell Lung Cancer Nucleo-Lung study prognostic value immunotherapy
Last updated: Sep 14, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk